| |
In vitro
|
In vivo
|
|---|
|
Non-diab.
|
Non-diab. + Pio
|
Non-diab.
|
Non-diab. + Pio
|
Diabetic
|
Diabetic + Pio
|
|---|
|
CD3+
|
14.4 % ± 0.4
|
17.8 % ± 1.0*
|
86.4 % ± 2.8
|
86.2 % ± 0.5
|
10.7 % ± 3.0*
|
64.3 % ± 3.3*
|
|
CD3+CD4+
|
12.7 % ± 0.7
|
3.7 % ± 0.3#
|
53.1 % ± 10
|
50.0 % ± 8.8
|
11 % ± 8.4#
|
27.3 % ± 3.9#
|
|
CD3+CD4+CD25+
|
6.6 % ± 0.4
|
33.1 % ± 3.4¶
|
12.4 % ± 1.8
|
19.0 % ± 0.5
|
4.6 % ± 2.1¶
|
36.2 % ± 7.1¶
|
- Splenocytes were labeled with rat anti-CD3 AF-647, anti-CD4 PE-Cy7, and anti-CD25 FITC. Results are % ± SD, n = 3
- In vitro non-diabetic + Pio versus non-diabetic: * p = 0.0085, # p = 0.0006, ¶ p = 0.0022
- In vivo diabetic versus non-diabetic (1): * p = 0.0087, # p = 0.0043, ¶ p = 0.0040
- Diabetic + Pio versus Diabetic (2): * p = 0.0135, # p = 0.0302, ¶ p = 0.0178
